8-K: OS Therapies Reports Q1 2025 Financial Results and Advances Osteosarcoma Treatment

OS Therapies announced its Q1 2025 financial results, highlighted by progress in its OST-HER2 osteosarcoma program and expansion of its immunotherapy platform.

Summary

• OS Therapies reported its financial results for the first quarter of 2025, which ended March 31, 2025.
• The company is focused on developing treatments for osteosarcoma and other solid tumors.
• A key highlight was the positive data from the Phase 2b clinical trial of OST-HER2 in preventing recurrent lung metastatic pediatric osteosarcoma.
• OS Therapies is preparing for a BLA submission to the FDA for OST-HER2 in Q3 2025.
• The company consolidated ownership of the listeria immunotherapy platform, adding clinical and preclinical assets.
• A new manufacturing patent extends exclusivity protection for the platform into 2040.
• The company secured research coverage from Wall Street analysts.
• The net operating loss for Q1 2025 was $3.876 million, compared to $1.490 million in Q1 2024.
• The increased loss was attributed to expenses related to the Phase 2b trial and regulatory preparations.
• The company expects feedback from a Type D FDA meeting by mid-June 2025.
• The company is on track for a Q3 2025 BLA filing for OST-HER2.
• The company's cash runway extends into mid-2026.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the positive clinical trial data, planned BLA submission, and expansion of the immunotherapy platform. However, the increased net operating loss and risks associated with forward-looking statements temper the overall sentiment.

Positives

• Positive data reported from the Phase 2b clinical trial of OST-HER2.
• Planned BLA submission for OST-HER2 in Q3 2025.
• Acquisition of the listeria cancer immunotherapy platform expands the pipeline.
• New patent extends exclusivity for the listeria platform to 2040.
• Formation of OS Drug Conjugates (OSDC) to focus on antibody drug conjugates.
• Scientific Advice Meeting with the UK MHRA planned for OST-HER2 approval.
• Positive data from canine osteosarcoma trials expanding the potential use of OST-HER2 into the prevention of amputation and control of lung metastases.
• The company's cash runway extends into mid-2026.

Negatives

• The net operating loss increased to $3.876 million in Q1 2025 from $1.490 million in Q1 2024.
• The increased loss was due to expenses related to the Phase 2b trial and regulatory preparations.

Risks

• The company's forward-looking statements are subject to risks and uncertainties, including FDA approval of OST-HER2.
• The company's financial results are subject to risks and uncertainties described in its filings with the SEC.

Future Outlook

OS Therapies anticipates submitting a BLA to the US FDA for OST-HER2 in osteosarcoma in 2025 and, if approved, would become eligible to receive a Priority Review Voucher that it could then sell.

Management Comments

• Paul Romness, MHP, Chairman & CEO of OS Therapies, stated that the first quarter of 2025 was a crucial execution quarter, with positive data from the OST-HER2 Phase 2b clinical trial.
• Chris Acevedo, Chief Financial Officer of OS Therapies, noted that one-time expenses related to the Phase 2b trial are largely behind them, and the company has dramatically reduced its burn rate, positioning it to operate into mid-2026.

Industry Context

OS Therapies is focused on developing treatments for osteosarcoma, a rare pediatric cancer, and is leveraging immunotherapy and antibody drug conjugate technologies. The company is seeking to bring the first new treatment for osteosarcoma to market in over 40 years.

Comparison to Industry Standards

• The company is pursuing Accelerated Approval from the FDA, Regenerative Medicine Advanced Therapy designation, and Breakthrough Therapy designation, which are common strategies for companies developing therapies for rare diseases with unmet needs.
• The company's approach of leveraging the immune-stimulatory effects of Listeria bacteria to target the HER2 protein is a novel approach in cancer immunotherapy.
• The company's development of tunable Antibody Drug Conjugates (tADC) is in line with the industry trend of developing more targeted and effective cancer therapies.

Stakeholder Impact

• Positive clinical trial data and potential FDA approval of OST-HER2 could benefit patients with osteosarcoma.
• The company's financial performance and pipeline development could impact shareholders.
• Expansion of the company's pipeline and commercialization efforts could create job opportunities.

Next Steps

• Receive feedback from Type D meeting with the FDA on the proposed statistical analysis plan of the OST-HER2 osteosarcoma program.
• Present the OST-HER2 Phase 2b osteosarcoma program data analyzed based upon FDA feedback at MIB Factor on June 28, 2025.
• Hold End of Phase 2 Meeting with FDA in Q3 2025 to review OST-HER2 Phase 2b osteosarcoma program data.
• Submit Projected BLA in Q3 2025 for OST-HER2 in the prevention of recurrent, fully resected, lung metastatic pediatric osteosarcoma.
• Hold Summer 2025 Scientific Advice Meeting (SAM) with MHRA for OST-HER2 osteosarcoma program, ILAP application submission and MHRA Conditional Marketing Authorisation application & decision.
• EMA National Competent Authority Scientific Advice Meeting Request (Medicines Evaluation Board, Netherlands) for OST-HER2 osteosarcoma program, EMA PRIME, EMA-FDA Parallel Scientific Advice application and EMA Conditional Marketing Authorisation application & decision.
• USDA meeting for OST-HER2 canine osteosarcoma program, conditional approval and initiation of pivotal clinical studies in preventive and therapeutic applications of OST-HER2 in osteosarcoma via subsidiary OS Animal Health.

Key Dates

Keywords

OST-HER2, osteosarcoma, immunotherapy, clinical trial, FDA, BLA, listeria, antibody drug conjugate, financial results, OS Therapies